Document Classification

Section Type: RESULTS

Text: Among patients without an elevated troponin level, there was no difference in the incidence of primary end point events between the abciximab group (23/499 patients [4. 6 %]) and the placebo group (22/474 patients [4. 6 %]) (RR, 0. 99 ; 95 % CI, 0. 56-1. 76 ; P =. 98), whereas among patients with an elevated troponin level, the incidence of events was significantly lower in the abciximab group (67/513 patients [13. 1 %]) compared with the placebo group (98/536 patients [18. 3 %]), which corresponds to an RR of 0. 71 (95 % CI, 0. 54-0. 95 ; P =. 02) (P =. 07 for interaction).